Cargando…

Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients

INTRODUCTION: Obstructive sleep apnea (OSA) is characterized by recurrent pauses in breathing during sleep leading to sleep fragmentation and further excessive daytime sleepiness. Therefore, OSA patients are at high risk of suffering from complications from psychiatric disorders. Serotonin is a know...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabryelska, A., Strzelecki, D., Sochal, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596651/
http://dx.doi.org/10.1192/j.eurpsy.2023.604
_version_ 1785125155007102976
author Gabryelska, A.
Strzelecki, D.
Sochal, M.
author_facet Gabryelska, A.
Strzelecki, D.
Sochal, M.
author_sort Gabryelska, A.
collection PubMed
description INTRODUCTION: Obstructive sleep apnea (OSA) is characterized by recurrent pauses in breathing during sleep leading to sleep fragmentation and further excessive daytime sleepiness. Therefore, OSA patients are at high risk of suffering from complications from psychiatric disorders. Serotonin is a known neurotransmitter and together with serotonin transporter (SERT) is involved in the development of depression and insomnia. OBJECTIVES: The study aimed to evaluate serotonin and SERT levels among OSA and healthy individuals and their association with insomnia and depression symptoms. METHODS: Forty individuals following polysomnography (PSG), based on the apnea-hypopnea index (AHI), were divided into 2 groups: the OSA group (AHI30; n=20) and the control group (AHI<5; n=20). Participants filled out questionnaires: Beck Depression Inventory (BDI) and Athens Insomnia Scale (AIS). Peripheral blood was collected in the morning after PSG. Protein concentrations were measured using ELISA. Further groups were divided into subgroups based on the standard cut-off points: without (AIS (-)) and with (AIS (+)) insomnia symptoms (AIS>5) and without (BDI (-)) and with (BDI (+)) depression symptoms BDI (BDI>19). RESULTS: No differences between the OSA and control groups in serotonin (128.8 (73.4 – 209.0) vs. 132.7 (69.9 – 214.6) ng/ml, p=0.805 and SERT (55.8 (39.7 – 64.80) vs. 576.4 (424.2 – 658.3) pg/ml, p=0.564) levels were observed. In OSA group SERT level correlated with AHI (r=0.409, p=0.043), desaturation index (r=0.504, p=0.024) and mean oxygen desaturation during night (r=-0.522, p=0.018), while serotonin level was associated with BMI (r=0.550, p=0.012), but not PSG parameters. Serotonin level was higher in the AIS (+) group but only in healthy individuals. Further, serotonin levels decreased in the BDI (+) group, yet this finding was observed only in the control group. CONCLUSIONS: The results show that serotonin levels are associated with the presence of insomnia in depression, but quite interestingly only among healthy individuals. The association between oxygen desaturation and SERT levels suggests the involvement of hypoxia in the serotonin signaling pathway. Yet further studies on larger populations are needed to better understand the mechanisms responsible for the development of psychiatric complications in OSA patients. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10596651
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105966512023-10-25 Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients Gabryelska, A. Strzelecki, D. Sochal, M. Eur Psychiatry Abstract INTRODUCTION: Obstructive sleep apnea (OSA) is characterized by recurrent pauses in breathing during sleep leading to sleep fragmentation and further excessive daytime sleepiness. Therefore, OSA patients are at high risk of suffering from complications from psychiatric disorders. Serotonin is a known neurotransmitter and together with serotonin transporter (SERT) is involved in the development of depression and insomnia. OBJECTIVES: The study aimed to evaluate serotonin and SERT levels among OSA and healthy individuals and their association with insomnia and depression symptoms. METHODS: Forty individuals following polysomnography (PSG), based on the apnea-hypopnea index (AHI), were divided into 2 groups: the OSA group (AHI30; n=20) and the control group (AHI<5; n=20). Participants filled out questionnaires: Beck Depression Inventory (BDI) and Athens Insomnia Scale (AIS). Peripheral blood was collected in the morning after PSG. Protein concentrations were measured using ELISA. Further groups were divided into subgroups based on the standard cut-off points: without (AIS (-)) and with (AIS (+)) insomnia symptoms (AIS>5) and without (BDI (-)) and with (BDI (+)) depression symptoms BDI (BDI>19). RESULTS: No differences between the OSA and control groups in serotonin (128.8 (73.4 – 209.0) vs. 132.7 (69.9 – 214.6) ng/ml, p=0.805 and SERT (55.8 (39.7 – 64.80) vs. 576.4 (424.2 – 658.3) pg/ml, p=0.564) levels were observed. In OSA group SERT level correlated with AHI (r=0.409, p=0.043), desaturation index (r=0.504, p=0.024) and mean oxygen desaturation during night (r=-0.522, p=0.018), while serotonin level was associated with BMI (r=0.550, p=0.012), but not PSG parameters. Serotonin level was higher in the AIS (+) group but only in healthy individuals. Further, serotonin levels decreased in the BDI (+) group, yet this finding was observed only in the control group. CONCLUSIONS: The results show that serotonin levels are associated with the presence of insomnia in depression, but quite interestingly only among healthy individuals. The association between oxygen desaturation and SERT levels suggests the involvement of hypoxia in the serotonin signaling pathway. Yet further studies on larger populations are needed to better understand the mechanisms responsible for the development of psychiatric complications in OSA patients. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10596651/ http://dx.doi.org/10.1192/j.eurpsy.2023.604 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Gabryelska, A.
Strzelecki, D.
Sochal, M.
Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title_full Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title_fullStr Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title_full_unstemmed Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title_short Evaluation of serotonin and serotonin transporter levels among Obstructive Sleep Apnea patients
title_sort evaluation of serotonin and serotonin transporter levels among obstructive sleep apnea patients
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596651/
http://dx.doi.org/10.1192/j.eurpsy.2023.604
work_keys_str_mv AT gabryelskaa evaluationofserotoninandserotonintransporterlevelsamongobstructivesleepapneapatients
AT strzeleckid evaluationofserotoninandserotonintransporterlevelsamongobstructivesleepapneapatients
AT sochalm evaluationofserotoninandserotonintransporterlevelsamongobstructivesleepapneapatients